Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?
This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing.
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of RXRX and EXAI
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) , relating to its proposed merger with Exscientia PLC.
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.11, signifying a -0.97% move from its prior day's close.
Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment
Recursion said it was able to use its AI-enabled drug discovery platform to identify a novel target and move all the way to gaining IND approval in less than 18 months.
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $6.67, indicating a -1.91% shift from the previous trading day.
Is Recursion Pharmaceuticals Stock a Buy?
Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 results for one of its products.
Cathie Wood's Stock Shuffle: 1 Stock She's Loving, 1 She's Leaving
Investors either love Cathie Wood or hate her. The founder of the Ark Invest family of exchange-traded funds can either be phenomenally successful or a dismal failure.
Recursion Stock Down Despite Meeting Goal in Brain Disease Study
RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.
Recursion's blood vessel disorder drug meets main goal in mid-stage study
Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a condition that causes blood vessel malformation met the main goal of safety and tolerability in a mid-stage study.
Is Recursion Pharmaceuticals a Warren Buffett Stock?
Recursion Pharmaceuticals lacks any of the long history of consistent performance that Buffett favors. Nonetheless, it aspires to become a business with characteristics he might like.
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma.
